Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma
Background and aims: Radiofrequency ablation (RFA) often results in incomplete ablation for medium-to-large and irregular tumors. To solve this clinical problem, we proposed a new treatment strategy of OK-432 in combination with an anti-programmed cell death protein 1 (αPD-1) antibody for residual t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223011423 |
| _version_ | 1797686875339620352 |
|---|---|
| author | Tao Sun Bo Sun Yanyan Cao Jiayun Liu Juan Chen Bin Liang Chuansheng Zheng Xuefeng Kan |
| author_facet | Tao Sun Bo Sun Yanyan Cao Jiayun Liu Juan Chen Bin Liang Chuansheng Zheng Xuefeng Kan |
| author_sort | Tao Sun |
| collection | DOAJ |
| description | Background and aims: Radiofrequency ablation (RFA) often results in incomplete ablation for medium-to-large and irregular tumors. To solve this clinical problem, we proposed a new treatment strategy of OK-432 in combination with an anti-programmed cell death protein 1 (αPD-1) antibody for residual tumors after incomplete RFA (iRFA) of hepatocellular carcinoma (HCC). Approach and results: The effect of OK-432 on immature dendritic cells (iDCs) was evaluated in vitro. A CCK-8 kit and ELISPOT were used to assess the killing effect of OK-432-induced CD8+ T cells in combination with an αPD-1 antibody on Hepa1–6 cells. We found that OK-432 significantly increased the maturation level of DCs, and OK-432-induced CD8+ T cells in combination with αPD-1 antibody significantly enhanced the function of CD8+ T cells. In the in vivo experiment, HCC model mice were treated with (1) pseudo iRFA + phosphate-buffered saline (PBS); (2) iRFA + PBS; (3) iRFA + OK-432; (4) iRFA + αPD-1; or (5) iRFA + OK-432 + αPD-1. We found that the combined therapy of OK-432 with αPD-1 antibody significantly increased the infiltration and function of CD8+ T cells and significantly decreased the number of FoxP3+ regulatory T cells in residual tumors after iRFA of HCC. Moreover, the smallest tumor volumes and the longest survival were observed in the triple combination treatment (iRFA+OK-432 +αPD-1 antibody) group compared with the other four groups. Conclusions: The combined therapy of OK-432 with αPD-1 antibody induced a strong antitumor immune response, which significantly inhibited the residual tumors after iRFA of HCC. This concept may provide a new treatment strategy to increase the curative efficacy of RFA for medium-to-large and irregular HCCs. Availability of data and material: The data of this study are available from the corresponding author on reasonable request. |
| first_indexed | 2024-03-12T01:10:55Z |
| format | Article |
| id | doaj.art-942ffaf9d95445248b603d7f9533989e |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T01:10:55Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-942ffaf9d95445248b603d7f9533989e2023-09-14T04:52:45ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-10-01166115351Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinomaTao Sun0Bo Sun1Yanyan Cao2Jiayun Liu3Juan Chen4Bin Liang5Chuansheng Zheng6Xuefeng Kan7Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, ChinaDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China; Corresponding authors at: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China; Corresponding authors at: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.Background and aims: Radiofrequency ablation (RFA) often results in incomplete ablation for medium-to-large and irregular tumors. To solve this clinical problem, we proposed a new treatment strategy of OK-432 in combination with an anti-programmed cell death protein 1 (αPD-1) antibody for residual tumors after incomplete RFA (iRFA) of hepatocellular carcinoma (HCC). Approach and results: The effect of OK-432 on immature dendritic cells (iDCs) was evaluated in vitro. A CCK-8 kit and ELISPOT were used to assess the killing effect of OK-432-induced CD8+ T cells in combination with an αPD-1 antibody on Hepa1–6 cells. We found that OK-432 significantly increased the maturation level of DCs, and OK-432-induced CD8+ T cells in combination with αPD-1 antibody significantly enhanced the function of CD8+ T cells. In the in vivo experiment, HCC model mice were treated with (1) pseudo iRFA + phosphate-buffered saline (PBS); (2) iRFA + PBS; (3) iRFA + OK-432; (4) iRFA + αPD-1; or (5) iRFA + OK-432 + αPD-1. We found that the combined therapy of OK-432 with αPD-1 antibody significantly increased the infiltration and function of CD8+ T cells and significantly decreased the number of FoxP3+ regulatory T cells in residual tumors after iRFA of HCC. Moreover, the smallest tumor volumes and the longest survival were observed in the triple combination treatment (iRFA+OK-432 +αPD-1 antibody) group compared with the other four groups. Conclusions: The combined therapy of OK-432 with αPD-1 antibody induced a strong antitumor immune response, which significantly inhibited the residual tumors after iRFA of HCC. This concept may provide a new treatment strategy to increase the curative efficacy of RFA for medium-to-large and irregular HCCs. Availability of data and material: The data of this study are available from the corresponding author on reasonable request.http://www.sciencedirect.com/science/article/pii/S0753332223011423Radiofrequency ablationHepatocellular carcinomaOK-432Programmed death-1 |
| spellingShingle | Tao Sun Bo Sun Yanyan Cao Jiayun Liu Juan Chen Bin Liang Chuansheng Zheng Xuefeng Kan Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma Biomedicine & Pharmacotherapy Radiofrequency ablation Hepatocellular carcinoma OK-432 Programmed death-1 |
| title | Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma |
| title_full | Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma |
| title_fullStr | Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma |
| title_full_unstemmed | Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma |
| title_short | Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma |
| title_sort | synergistic effect of ok 432 in combination with an anti pd 1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma |
| topic | Radiofrequency ablation Hepatocellular carcinoma OK-432 Programmed death-1 |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223011423 |
| work_keys_str_mv | AT taosun synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT bosun synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT yanyancao synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT jiayunliu synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT juanchen synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT binliang synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT chuanshengzheng synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma AT xuefengkan synergisticeffectofok432incombinationwithanantipd1antibodyforresidualtumorsafterradiofrequencyablationofhepatocellularcarcinoma |